Pfizer vs. Gilead: Which Drugmaker Has the Stronger Growth Story?
Pfizer vs. Gilead: Which Drugmaker Has the Stronger Growth Story? Noor Ul Ain Rehman Sun, August 23, 2026 at 12:54 PM PDT 4 min read GILD PFE The next few years will test whether Pfizer Inc. (NYSE: PFE ) can replace yesterday's blockbusters, and whether Gilead Sciences, Inc. (NASDAQ: GILD ) can become more than an HIV company. Pfizer's (NYSE:PFE) newer medicines are gaining traction, but that growth has yet to accelerate the wider business. Gilead (NASDAQ:GILD) is expanding faster, although its performance remains concentrated in one therapeutic area. For investors, this is ultimately a choice between an unfinished turnaround and a stronger growth story still searching for greater breadth. 5 Fastest Growing Health Tech Companies in the World Bull Case Pfizer's (NYSE:PFE) strongest result was the performance of its non-COVID portfolio. Revenue excluding Comirnaty and Paxlovid grew 5% operationally, while launched and acquired products generated $3.2 billion and increased 18...
Comments
Post a Comment